• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Services
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery
• TIL Therapy Development
  • Special TIL Therapy Development
  • One-Stop TIL Development
• CIK Therapy Development
  • One-Stop CIK Therapy Development
  • CIK Therapy Improvement

CellRapeutics™ In Vivo B Cell Engineering Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The Prospect of In Vivo B Cell Engineering

Ex vivo engineering of B cells to produce target-specific antibodies has proven to be an effective pathway for treating disease. However, there are some limitations to the specific application of this strategy, such as the complex procedures ex vivo, and MHC compatibility between donor and recipient cells. To address these issues, in vivo B cell engineering serves as a safer, cost-effective, and scalable approach to producing targeted therapeutic antibodies.

Fig.1 BCR editing clinical approach.¹

Our CellRapeutics™ In Vivo B Cell Engineering Service

With our superior technology platform, Creative Biolabs specializes in providing cost-effective CellRapeutics™ in vivo B cell engineering services for global customers. Our CellRapeutics™ in vivo B cell engineering service incorporates cutting-edge technologies such as CRISPR/Cas9 to integrate the coded genes and engineered viral vectors such as AAV into a desired site in the B cell genome. In addition, we offer a full range of high-quality in vivo B cell engineering services, including vector optimization, and animal model establishment, to generate compelling data to suitable for our clients' B cell research and project development.

Fig.2 Anti-HIV-1 broadly neutralizing antibodies induced by natural immunity, trained immunity, and engineered immunity. (Sun, et al., 2023)

Highlight Features

Published Data

Representative data: These grants reveal, for the first time, that B cells may be safely and robustly created in vivo. In mice, a single systemic dosage of dual AAV-DJ coding for CRISPR-Cas9 and donor cassettes enabled site-specific integration with little off-target Cas9 expression and DNA double-strand breaks. Following immunization, the engineered B cells were activated by antigens, resulting in memory retention, clonal selection, and differentiation into plasma cells that release neutralizing amounts of bNAb.

Frequently Asked Question

Q1: Can in vivo engineered B cells be used to generate therapeutic antibodies?

A1: In vivo B cell engineering is a safe, potent, and scalable technology that might be used to treat not just infectious diseases but also noncommunicable diseases including cancer and autoimmune disease.

For more details about our CellRapeutics™ in vivo B cell engineering service, please contact us with no hesitation. We are sincerely looking forward to working with global customers.

References

1. Page, Audrey, et al. "Exploiting B cell transfer for cancer therapy: engineered B cells to eradicate tumors." International Journal of Molecular Sciences 22.18 (2021): 9991.
2. Sun, Caijun, Teng Zuo, and Ziyu Wen. "B cell engineering in vivo: Accelerating induction of broadly neutralizing antibodies against HIV-1 infection." Signal Transduction and Targeted Therapy 8.1 (2023): 13.